Merck Provides Update on Next Steps for TREDAPTIVE™ (extended-release niacin/laropiprant)
07:39 EST 11 Jan 2013 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Merck (NYSE: MRK), known as MSD outside of the United States and Canada,
today announced the company is taking steps to suspend the availability
of TREDAPTIVE™ (extended-release niacin/laropiprant) tablets
worldwide. TREDAPTIV...
Other Sources for this Article
Merck
Media:
Pamela Eisele, 908-423-5042
or
Skip
Irvine, 267-305-5397
or
Investors:
Carol Ferguson,
908-423-4465
or
Justin Holko, 908-423-5088
More From BioPortfolio on "Merck Provides Update on Next Steps for TREDAPTIVE™ (extended-release niacin/laropiprant)"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
